⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20400737 | 0.94 | MPO (0.37) | — | |
| SCHEMBL3217459 | 0.86 | — | — | |
| SCHEMBL21626278 | 0.67 | DRD2 (0.35) | — | |
| SCHEMBL21626241 | 0.67 | RECQL (0.30) | — | |
| SCHEMBL21626287 | 0.67 | — | — | |
| SCHEMBL19550637 | 0.67 | — | — | |
| SCHEMBL21626282 | 0.67 | DRD2 (0.34) | — | |
| SCHEMBL30405199 | 0.66 | CDC7 (0.46) | — | |
| SCHEMBL15046539 | 0.65 | MPO (0.39) | — | |
| SCHEMBL31572532 | 0.65 | MPO (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4611899-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | Petra Pharma Corporation (US) | 2025-09-10 | — | — | EP | claimed |
| US-20240182460-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION | 2024-06-06 | — | — | US | claimed |
| WO-2024097172-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION (US) | 2024-05-10 | — | — | WO | claimed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | claimed |
| EP-4093509-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2022-11-30 | — | — | EP | claimed |
| EP-4667054-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| US-20250353862-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2025-11-20 | — | — | US | disclosed |
| US-12421225-B2 | Heteroaromatic amide derivative and medicament containing the same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2025-09-23 | — | — | US | disclosed |
| EP-4611899-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | Petra Pharma Corporation (US) | 2025-09-10 | — | — | EP | disclosed |
| US-12404283-B2 | c-MYC mRNA translation modulators and uses thereof in the treatment of cancer | ANIMA BIOTECH INC. (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4463452-B1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC (US) | 2025-07-30 | — | — | EP | disclosed |
| EP-3880660-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| US-9023844-B2 | Heterocyclylpyri (mi) dinylpyrazole as fungicidals | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-20140256677-A1 | HETEROCYCLYLPYRI (MI) DINYLPYRAZOLE AS FUNGICIDALS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-11 | — | — | US | disclosed |
| US-8188083-B2 | Triazolopyridazines | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188083-B2 | Triazolopyridazines | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090270402-A1 | Novel triazolopyridazines | ABBVIE INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270402-A1 | Novel triazolopyridazines | ABBVIE INC. | 2009-10-29 | — | — | US | disclosed |
| WO-2009005675-A1 | NOVEL TRIAZOLOPYRIDAZINES | ABBOTT LABORATORIES (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2008059238-A1 | BENZENESULFONAMIDE COMPOUNDS AS EDG-1 ANTAGONISTS USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | WO | disclosed |